These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21069104)

  • 41. Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations.
    Truong DD; Bhidayasiri R
    Eur J Neurol; 2006 Feb; 13 Suppl 1():36-41. PubMed ID: 16417596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic uses of botulinum toxin.
    Wheeler AH
    Am Fam Physician; 1997 Feb; 55(2):541-5, 548. PubMed ID: 9054223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Videofluoroscopy-guided botulinum toxin for pharyngoesophageal spasm: a promising advance in laryngectomy rehabilitation.
    Maniaci A; Lavalle S; Mayo-Yanez M; Parisi FM; Cocuzza S
    Eur Arch Otorhinolaryngol; 2024 Jun; 281(6):3305-3306. PubMed ID: 38456929
    [No Abstract]   [Full Text] [Related]  

  • 44. Botulinum toxin therapy of migraine and tension-type headache: comparing different botulinum toxin preparations.
    Schulte-Mattler WJ; Martinez-Castrillo JC
    Eur J Neurol; 2006 Feb; 13 Suppl 1():51-4. PubMed ID: 16417598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dystonia and headaches: clinical features and response to botulinum toxin therapy.
    Galvez-Jimenez N; Lampuri C; Patiño-Picirrillo R; Hargreave MJ; Hanson MR
    Adv Neurol; 2004; 94():321-8. PubMed ID: 14509690
    [No Abstract]   [Full Text] [Related]  

  • 46. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences.
    Barnes MP; Best D; Kidd L; Roberts B; Stark S; Weeks P; Whitaker J
    Eur J Neurol; 2005 Dec; 12(12):947-55. PubMed ID: 16324088
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group.
    Berardelli A; Formica A; Mercuri B; Abbruzzese G; Agnoli A; Agostino R; Caraceni T; Carella F; De Fazio G; De Grandis D
    Ital J Neurol Sci; 1993 Jun; 14(5):361-7. PubMed ID: 8354632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A survey about the accessibility to botulinum toxin therapy for dystonia].
    Mezaki T; Hayashi A; Nakase H; Hasegawa K
    No To Shinkei; 2006 Mar; 58(3):219-24. PubMed ID: 16629446
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Botulinum toxin therapy for cervical dystonia.
    Walker FO
    Phys Med Rehabil Clin N Am; 2003 Nov; 14(4):749-66, vi. PubMed ID: 14580035
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neurobiological basis for the use of botulinum toxin in pain therapy.
    Mense S
    J Neurol; 2004 Feb; 251 Suppl 1():I1-7. PubMed ID: 14991335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The evolution of botulinum neurotoxin type A for cosmetic applications.
    Carruthers J; Carruthers A
    J Cosmet Laser Ther; 2007 Sep; 9(3):186-92. PubMed ID: 17763029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurotoxins licensed as treatment for neck neuromuscular disorder.
    Am J Health Syst Pharm; 2001 Feb; 58(3):200, 202. PubMed ID: 11217174
    [No Abstract]   [Full Text] [Related]  

  • 53. [Botulinum toxin--phenomenon of poison].
    Berny-Moreno J; Barancewicz-Losek M
    Pol Merkur Lekarski; 2006 Apr; 20(118):482-5. PubMed ID: 16886581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Botulinum toxin products overview.
    Carruthers A; Carruthers J
    Skin Therapy Lett; 2008; 13(6):1-4. PubMed ID: 18806905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Injectable neuromodulatory agents: botulinum toxin therapy.
    Frenkl TL; Rackley RR
    Urol Clin North Am; 2005 Feb; 32(1):89-99. PubMed ID: 15698881
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Restoring balance in focal limb dystonia with botulinum toxin.
    Sheean G
    Disabil Rehabil; 2007 Dec; 29(23):1778-88. PubMed ID: 18033603
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of botulinum toxin in the treatment of cervical dystonia.
    Molho E; Jankovic J; Lew M
    Neurol Clin; 2008 May; 26 Suppl 1():43-53. PubMed ID: 18603167
    [No Abstract]   [Full Text] [Related]  

  • 58. Botulinum toxin for people with dystonia treated by an outreach nurse practitioner: a comparative study between a home and a clinic treatment service.
    Whitaker J; Butler A; Semlyen JK; Barnes MP
    Arch Phys Med Rehabil; 2001 Apr; 82(4):480-4. PubMed ID: 11295008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of botulinum toxin-B (BTX-B) injections for hemifacial spasm.
    Tousi B; Perumal JS; Ahuja K; Ahmed A; Subramanian T
    Parkinsonism Relat Disord; 2004 Oct; 10(7):455-6. PubMed ID: 15465407
    [No Abstract]   [Full Text] [Related]  

  • 60. Hemimasticatory spasm treated with botulinum toxin: case report.
    Teive HA; Piovesan EJ; Germiniani FM; Camargo CH; Sa D; Scola RH; Werneck LC
    Arq Neuropsiquiatr; 2002 Jun; 60(2-A):288-9. PubMed ID: 12068362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.